HAE patients mostly attack-free after gene-editing therapy: Data
In the years following treatment with the gene-editing therapy lonvoguran ziclumeran, or lonvo-z — also known as NTLA-2002 — most people with hereditary angioedema (HAE) taking part in a clinical trial have been completely free from swelling attacks without the need for long-term preventive therapy. That’s according to…